1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163784
    AKR1C3-IN-14
    Inhibitor
    AKR1C3-IN-14 (compound 4) is an AKR1C3 inhibitor (IC50=0.122 μM) that reduces the overproduction of androgens by inhibiting the activity of the AKR1C3 enzyme, thereby regulating hormone-mediated signaling. AKR1C3-IN-14 also plays a role in the biosynthesis of the prostaglandin PGF2α, regulating cell proliferation by affecting this pathway. AKR1C3-IN-14 can be used in the study of prostate cancer.
    AKR1C3-IN-14
  • HY-N0539R
    Calceolarioside B (Standard)
    Calceolarioside B (Standard) is the analytical standard of Calceolarioside B (HY-N0539). This product is intended for research and analytical applications. Calceolarioside B is a phenylethanoid glycoside. Calceolarioside B can be isolated from the leaves of Akebia quinata. Calceolarioside B inhibits RLAR activity with an IC50 value of 23.99 μM. Calceolarioside B inhibits the entry of Omicron BA.2 into host cells. Calceolarioside B reduces IL-6 levels. Calceolarioside B has immunomodulatory activity. Calceolarioside B has anticancer activity against human hormone-independent prostate cancer.
    Calceolarioside B (Standard)
  • HY-N1517A
    (Rac)-Ganoderic acid C2
    Inhibitor
    (Rac)-Ganoderic acid C2 is the racemate of Ganoderic acid C2 (HY-N1517). Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses anti-tumor, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM[.
    (Rac)-Ganoderic acid C2
  • HY-N12871
    Floramanoside D
    Inhibitor
    Floramanoside D is a flavonol glycoside. Floramanoside D inhibits aldose reductase (IC50 is 2.2 μM), scavenges the 2,2-diphenyl-1-picrylhydrazyl (DPPH) (SC50 is 12.5 μM).
    Floramanoside D
  • HY-W040288A
    L-Threose (solution),0.5M
    Substrate
    L-Threose (solution), 0.5M is a 0.5 M solution of L-Threose in water. L-Threose is a substrate for Aldose Reductase and may prevent protein glycation.
    L-Threose (solution),0.5M
  • HY-181542
    SG-55
    Inhibitor
    SG-55 is a selective, noncompetitive and orally active AKR1C3 inhibitor with an IC50 of 5 nM and a Ki of 10 nM. SG-55 shows >2000-fold selectivity for AKR1C3 over AKR1C1, AKR1C2, and AKR1C4 (> 10 μM). SG-55 increases the ratio of reduced/oxidized nicotinamide adenine dinucleotide phosphate (NADPH/NADP+), decreases the ratio of reduced/oxidized glutathione (GSH/GSSG), and induces DNA double-strand breaks. SG-55 can overcome Osimertinib (HY-15772) resistance mediated by EGFR C797S triple mutation in non-small cell lung cancer (NSCLC).
    SG-55
  • HY-155502
    AKR1C3-IN-10
    Inhibitor
    AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC50=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model.
    AKR1C3-IN-10
  • HY-N0311R
    Emodin-8-glucoside (Standard)
    Inhibitor
    Emodin-8-glucoside (Standard) is the analytical standard of Emodin-8-glucoside. This product is intended for research and analytical applications. Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier.
    Emodin-8-glucoside (Standard)
  • HY-177415
    JSD26
    Inhibitor
    JSD26 is a selective and orally active SCoR2 (AKR1A1) inhibitor with an IC50 of 93 nM. JSD26 has 10-fold selectivity for SCoR2 versus AKR1B1. JSD26 can be used for the study acute kidney injury (AKI).
    JSD26
  • HY-115940
    Aldose reductase-IN-2
    Inhibitor
    Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent.
    Aldose reductase-IN-2
  • HY-113850
    CPSA
    Inhibitor
    CPSA is a potent and competitive inhibitor against 20α-hydroxysteroid dehydrogenase (AKR1C1) with a Ki value of 0.86 nM. CPSA is promising for research of lung and endometrial cancers, premature birth and neuronal disorders.
    CPSA
  • HY-163323
    AKR1C3-IN-12
    Inhibitor
    AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer.
    AKR1C3-IN-12
  • HY-150646
    S07-2009
    Inhibitor
    S07-2009 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.20 μM.
    S07-2009
  • HY-151946
    ALR2-IN-2
    Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
    ALR2-IN-2
  • HY-115977
    Aldose reductase-IN-3
    Inhibitor
    Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.
    Aldose reductase-IN-3
  • HY-101555
    M 16209
    Inhibitor
    M 16209 is an orally active aldose reductase (AR) inhibitor. M 16209 inhibits partially purified AR from various sources with IC50 values of 0.12, 0.24, 4.5, 1.2 and 9.3 μM for rat lens AR, bovine lens AR, bovine kidney AR, canine lens AR and human placental AR. M 16209 can be used for the research of metabolic disease, such as diabetes.
    M 16209
  • HY-N6883
    6-Methoxytricin
    Inhibitor
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent.
    6-Methoxytricin
  • HY-113738
    ADN 138
    Inhibitor
    ADN-138 is an aldose reductase inhibitor. ADN-138 reduces sorbitol levels in diabetic nerves and results in significant increases in MNCV and Na+, K+-ATPase in the nerves. ADN-138 can be used in the research of diabetic nerve complications.
    ADN 138
  • HY-N2494
    Hydroxyevodiamine
    Inhibitor
    Hydroxyevodiamine inhibits aldose reductase with an IC50 value of 24.1 μM.
    Hydroxyevodiamine
  • HY-100969
    EBPC
    Inhibitor
    EBPC is a potent and selective aldose reductase inhibitor with an IC50 of 47 nM.
    EBPC
Cat. No. Product Name / Synonyms Application Reactivity